EA Series Trust’s Ginkgo Bioworks DNA Stock Holding History

EA Series Trust’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$31.5K	Buy	+423	New	+$25K	﹤0.01%	1116

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EA Series Trust's DNA Position: Q2 2023 in Review

EA Series Trust opened a new position in Ginkgo Bioworks (DNA) in Q2 2023: 423 shares worth $31.5K. The stake represents ﹤0.01% of the portfolio and ranks #1116 among its holdings.

315 funds tracked by Wall St. Rank hold DNA as of Q2 2023.

EA Series Trust held 423 shares of Ginkgo Bioworks worth $31.5K as of Q2 2023.
Ginkgo Bioworks was a new EA Series Trust position in Q2 2023.
Ginkgo Bioworks made up ﹤0.01% of EA Series Trust's portfolio in Q2 2023, its #1116 holding.
315 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.